Neurocrine Biosciences (NBIX) 10-Q2024 Q2 Quarterly report

Filed: 1 Aug 24, 7:04am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acid, agonist, allosteric, AMPA, antagonist, antidepressant, approach, capsule, CEO, downtime, ENDO, Endocrine, England, episode, final, healthy, Hedging, Journal, leadership, MDD, mid, modulator, motivated, NAM, NMDA, notification, PAM, parallel, PDUFA, predefined, propionic, randomized, ratably, reassessed, retire, SAVITRI, settlement, skilled, Society, solution, tenant, topline, toxicity, vacated, Vice, viewed, withholding

Removed: adjustment, automatically, calendar, call, closing, deficit, drop, ending, epidemic, equal, experimental, expressly, fundamental, history, inception, insensitive, merger, met, negotiated, outstanding, privately, rank, redeem, redemption, remained, restrictive, subordinated, turn, unpaid, unsecured

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated NBIX transcripts

NBIX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATIONS OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934; and

(2)That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


August 1, 2024	By:	/s/ Kevin C. Gorman
	Name:	Kevin C. Gorman
	Title:	Chief Executive Officer

In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934; and

(2)That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


August 1, 2024	By:	/s/ Matthew C. Abernethy
	Name:	Matthew C. Abernethy
	Title:	Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.